Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 22, 2024 07:01 ET
|
Rhythm Pharmaceuticals, Inc.
-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 -- -- Significant unmet need with 5,000...
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
February 22, 2024 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Fourth quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
February 08, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
February 07, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
January 31, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
January 12, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
January 04, 2024 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation -- -- Rhythm to advance LB54640 in two Phase 2 clinical trials -- BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm...
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
January 04, 2024 06:58 ET
|
Rhythm Pharmaceuticals, Inc.
-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE® (setmelanotide) to treat patients with Bardet-Biedl syndrome and...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
December 15, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
December 13, 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases -- -- Approximately 150 healthcare professionals...